07 March 2024

NETLA/13/PR50722/2024 – being conducted as a market assessment study

In connection with the implementation of the project titled “Development(Description) and development of an innovative solution – a complex, two-component medicinal product in the form of eye drops in a multi-dose package without preservatives, aimed at the treatment of open-angle glaucoma”, funded from the state budget by the Medical Research Agency, Pharmaceutical Works Polpharma S.A., you are kindly requested to submit a bid for the purchase and delivery of reference standards of the active substance – netarsudil dimesylate and R-enantiomer of netarsudil dimesylate.

Details of the price inquiry can be found in the documents attached below.

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.